Антибактериальная терапия внебольничной пневмонии: что нового?


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Внебольничная пневмония (ВП) остается распространенным и потенциально жизнеугрожающим заболеванием. Доступность новых антибиотиков открывает возможности для расширения эмпирической терапии больных ВП, вызываемой лекарственно устойчивыми возбудителями. Однако при этом необходимо убедиться в том, что новые антибиотики эффективны и хорошо переносятся пациентами, а также в том, что их применение целесообразно с точки зрения минимизации риска развития антибиотикорезистентности. Успех лечения ВП зависит от неотложного применения антибиотиков, эффективных в отношении вероятных возбудителей, врачи должны учитывать тяжесть течения заболевания и преобладающие региональные особенности антибиотикорезистентности в процессе выбора соответствующей лечебной тактики.

Полный текст

Доступ закрыт

Об авторах

А. И Синопальников

Российская медицинская академия непрерывного профессионального образования

Email: aisyn@list.ru
д.м.н., профессор, зав. кафедрой пульмонологии Москва, Россия

Список литературы

  1. The top 10 causes of death. Geneva: World Health Organization, 2013. URL: http://www.who.int/mediacentre/factsheets/fs310/en/index.html
  2. Murphy S.L., Xu J., Kochanek K.D. Deaths: preliminary data for 2010. Natl Vital Stat Rep. 2012;60:1-51.
  3. Ferreira-Coimbra J., Sarda C., Rello J. Burden of community-acquired pneumonia and unmet clinical needs. Adv Ther. 2020;37:1302-18. doi: 10.1007/s12325-020-01248-7.
  4. Wunderink R.G., Waterer G.W. Community-acquired pneumonia. N Engl J Med. 2014;370:543-51. doi: 10.1056/NEJMcp1214869.
  5. Внебольничная пневмония у взрослых. Клинические рекомендации (2021). Доступно на: https://cr.minzdrav.gov.ru
  6. Cilloniz C., Dominedo C., Garcia-Vidal C., Torres A. Community-acquired pneumonia as an emergency condition. Curr Opin Crit Care 2018;24:531-39. doi: 10.1097/MCC.0000000000000550.
  7. Kollef M.H., Betthauser K.D. New antibiotics for community-acquired pneumonia. Curr Opin Infect Dis. 2019;32:169-75. Doi: 10.1097/ QCO.0000000000000526.
  8. Liapikou A., Cilloniz C., Palomepue A., Torres T. Emerging antibiotics for community-acquired pneumonia. Expert Opin Emerg Drugs. 2019;24(4):221-31. doi: 10.1080/14728214.2019.1685494.
  9. Pereira J.M., Goncalves-Pereira J., Ribeiro O., et al. Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the iNFAUCi study J Crit Care 2018;43:183-89. Doi: 10.1016/j.
  10. Cilloniz C., Gabarrus A., Ferrer M., et al. Community-acquired pneumonia due to multidrug- and nonmultidrug-resistant Pseudomonas aeruginosa. Chest. 2016;150:415-25. Doi: 10.1016/j. chest.2016.03.042.
  11. Iannini P.B., Paladino J.A., Lavin B., et al. A case series of macrolide treatment failures in community acquired pneumonia. J Chemother. 2007;19:536-doi: 10.1179/joc.2007.19.5.536.
  12. Aguilar P.R., Balsara K., Itoh A., Kollef M.H. A noteworthy case of acute bronchitis. Ann Am Thorac Soc. 2016;13:285-87. Doi: 10.1513/ AnnalsATS.201508-518CC.
  13. Waterer G.W., Wunderink R.G., Jones C.B. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest. 2000;118:1839-40. Doi: 10.1378/ chest.118.6.1839-a.
  14. Brown E.D., Wright G.D. Antibacterial drug discovery in the resistance era. Nature. 2016;529:336-43. doi: 10.1038/nature17042.
  15. Lewis K. Platforms for antibiotic discovery Nat Rev Drug Discov. 2013;12:371-83. Doi: 10.1038/ nrd3975.
  16. Lewis K. Antibiotics: Recover the lost art of drug discovery. Nature. 2012;485:4390440. doi: 10.1038/485439a.
  17. Schatz A., Bugie E., Waksman S.A. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. ProcSoc Exp Biol Med. 1944;55:66-9. doi: 10.1097/01. blo.0000175887.98112.fe.
  18. Browne K., Chakraborty S., Chen R., et al. A new era of antibiotics: the clinical potential of antimicrobial peptides. Int J Mol Sci. 2020;21:7047. doi: 10.3390/ijms21197047.
  19. Lewis K. The science of antibiotic discovery Cell. 2020;181:29-45. Doi: 10.1016/j. cell.2020.02.056.
  20. Peyrani P., Mandell L., Torres A., Tillotson G.S. The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance. Expert Rev Respir Med. 2019;13:139-52. doi: 10.1080/17476348.2019.1562339.
  21. Spellberg B., Srinivasan A., Chambers H. New societal approaches to empowering antibiotic stewardship. JAMA. 2016;315:1229-30. doi: 10.1001/jama.2016.1346.
  22. Cilloniz C., Ardanuy C., Vila J., Torres A. What in the clinical relevance of drug-resistant pneumococcus? Curr Opin Pulm Med. 2016;22:227-34. doi: 10.1097/MCP0000000000000262.
  23. The 10x'20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020. CID. 2010;50:1081-83. doi: 10.1086/652237.
  24. Iizawa Y., Nagai J., Ishikawa T., et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother. 2004;10:146-56. doi: 10.1007/s10156-004-0309-3.
  25. Sader H.S., Fritsche T.R., Kaniga K., et al. Аntimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother. 2005;49:3501-12. doi: 10.1128/AAC.49.8.3501-3512.2005.
  26. Ghuysen J.M. Molecular structures of penicillin-binding proteins and ß-lactamases. Trends Micribiol. 1994;2:372-80. doi: 10.1016/0966-842x(94)90614-9.
  27. Kosowska-Shick K., McGhee P., Appelbaum P Affinity of ceftaroline and other ß-lactams for penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010;54:1670-77. doi: 10.1128/AAC.00019-10.
  28. Sader H.S., Fritsche T.R., Jones R.N. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2008;52:1 153-55. doi: 10.1128/AAC.01351-07.
  29. Saravolatz L., Pawlak J., Johnson L. In vitro activity of ceftaroline against community-associated methicillin-resistanT., vancomycin-intermediate, vancomycin-resistanT., and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2010;54:3027-30. doi: 10.1128/AAC.01516-09.
  30. Jacqueline C., Amador G., Batard E., et al. Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. J. Antimicrob. Chemother. 2011;6:863-66. doi: 10.1093/jac/dkr019.
  31. Fenoll A., Aguilar L., Robledo O., et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother. 2008;52:4209-10. doi: 10.1128/AAC.00712-08.
  32. Patel S.N., Pillai D.R., Pong-Porter S., et al. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008. J Antimicrob Chemother. 2009;64:659-60. doi: 10.1093/jac/ dkp231.
  33. File T.M., Low D.E., Eckburg P.B., et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of caftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl.):iii19-32. doi: 10.1093/jac/ dkr096.
  34. Low D.E., File T.M., Eckburg P.B., et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of caftaroline fosamil versus ceftriaxone in communityacquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl.):iii33-44. doi: 10.1093/jac/ dkr097.
  35. Shorr A.F., Kollef M., Eckburg P.B., et al. Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials. Diagn Microbiol Infect Dis. 2013;75:298-303. doi: 10.1016/j. diagmicrobio.2012.12.002.
  36. Ramirez J.A., Srinath L., Ahkee S., et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995;155:1273- 76.
  37. Ramirez J.A., Vargas S., Ritter G.W., et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med. 1999;159:2449-54. doi: 10.1001/ archinte.159.20.2449.
  38. Carreno J.J., Lodise T.P. Ceftaroline fosamil for the treatment of community-acquired pneumonia: from FOCUS to CAPTURE. Infect Dis. Ther. 2014;3:123-32.
  39. Bassetti M., Russo A., Cilloniz C., et al. Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. Int J Antimicrob Agents. 2020;55:105921. doi: 10.1016/j.ijantimicag.2020.105921.
  40. Metlay J.P., Waterer G.W., Long A.C., et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(iss 7):e45-67. doi: 10.1164/ rccm.201908-1581ST.
  41. Duraes F., Sousa E. Omadacycline: A Newly approved antibacterial from the class of tetracyclines. Pharmaceuticals (Basel). 2019;12(2):63. doi: 10.3390/ph12020063.
  42. Noel G.J., Draper M.P., Hait H., et al. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012;56:5650-4. doi: 10.1128/AAC.00948-12.
  43. Gotfried M.H., Horn K., Garrity-Ryan L., et al. Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects. Antimicrob Agents Chemother. 2017;61:e01135-17. doi: 10.1128/AAC.01135-17.
  44. Villano S., Steenbergen J., Loh E. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol. 2016;11:1421-34. doi: 10.2217/fmb-2016-0100.
  45. URL: https://www.clinicaltrials.gov/ct2/show/results/NCT02531438?term=omadacycline&ra nk=4
  46. Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial Pneumonia". www.globenewswire.com. April 3, 2017. Retrieved.
  47. URL:https://www.drugs.com/history/nuzyra.html
  48. Llano-Sotelo B., Dunkle J., Klepacki D., et al. Binding and action of CEM-101, a new Accepted Manuscript fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob. Agents Chemother. 2010;54:4961970. doi: 10.1128/AAC.00860- 10.
  49. Zhanel G.G., Hartel E., Adam H., et al. Solithromycin: a novel fluoroketolide for the treatment of community-acquired bacterial pneumonia. Drugs. 2016;76:1737-57. doi: 10.1007/s40265-016-0667-z.
  50. McGhee P., Clark C., Kosowska-Shick K.M., et al. In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob Agents Chemother. 2010;54:230-8. doi: 10.1128/AAC.01123-09.
  51. Jamieson B.D., Ciric S., Fernandes P. Safety and pharmacokinetics of solithromycin in subjects with hepatic impairment. Antimicrob Agents Chemother. 2015;59:4379-86. doi: 10.1128/ AAC.04652-14.
  52. Rodvold K.A., Gotfried M.H., Still J.G., et al. Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects. Antimicrob Agents Chemother. 2012;56:5076-81. doi: 10.1128/AAC.00766-12.
  53. Oldach D., Clark K., Schranz J., et al. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother. 2013;57:2526-34. doi: 10.1128/AAC.00197- 13.
  54. File T.M., Rewerska B., Tanaseanu C.M., et al. SOLITAIRE-IV: A randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia. Clin Infect.Dis. 2016;63:1007-16. doi: 10.1093/cid/ ciw490.
  55. Fernandes P., Martens E., Bertrand D., Pereira D. The solithromycin journey -it is all in the chemistry. Bioorg Med Chem. 2016;24:6420-8. doi: 10.1016/j.bmc.2016.08.035.
  56. FDA Briefing document Soiithromycin Oral Capsule and Injection Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC). URL: https://www.fda.gov.2016
  57. Guo B., Wu X., Zhang Y., et al. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fiuorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Clin Drug Invest. 2012;32:475-86. doi: 10.2165/11632780-000000000-00000.
  58. Liu Y., Zhang Y., Wu J., et al. A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of communityacquired pneumonia. J Microbiol Immunol Infect. 2017;50:811-20. doi: 10.1016/j.jmii.2015.09.005.
  59. van Rensburg D.J., Perng R.P., Mitha I.H., et al. Efficacy and safety of nemonoxacin Accepted Manuscriptversus levofloxacin for community acquired pneumonia. Antimicrob Agents Chemother. 2010;54:4098-106. doi: 10.1128/ AAC.00295-10.
  60. Cheng S., Wu R., Hsu Z., et al. Efficacy and safety of oral nemonoxacin in treatment of community-acquired pneumonia: subgroup analysis results in Taiwanese patients in a randomized, double-blind, multi-center, phase III comparative study with levofloxacin. 2015. Available at: www.atsjournals.org/doi/abs/10.1164/ajrccmconference 2015.191.1_Meeting Abstracts.A4063.
  61. Marra A., Bortolon E., Molstad D., et al. Evaluation of delafloxacin in rat granuloma pouch infections caused by gram-negative pathogens. In program and Abstract of 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA: Abstract; 2011. A1-680.
  62. Remy J.M., Tow-Keogh C.A., McConnell T.S., et al. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother. 2012;67:2814-20. doi: 10.1093/jac/dks307.
  63. Pfaller M.A., Sader H.S., Rhomberg P.R., Flamm R.K. In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother. 2017;61:e02609-16. doi: 10.1128/ AAC.02609-16.
  64. Sheikh J. Clinical microbiology review. Delafloxacin. NDA#208610, 208611. Melinta Therapeutics, Inc. Division of Anti-Infective Products. Center for Drug Evaluation and Research. US Food and Drug Administration; 2017.
  65. Thabit A.K., Crandon J.L., Nicolau D.P Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. Int J Antimicrob Agents. 2016;48:535-41. doi: 10.1016/j.ijantimicag.2016.08.012.
  66. URL: https://www.ciinicaitriais.gov/ct2/resuits?cond=&term=NCT02679573&cntry=&state=&ciy=&dist=
  67. Kocsis B., Domokos J., Szabo D. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofioxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob. 2016;15:34. doi: 10.1186/s12941-016-0150-4.
  68. Fernandes P., Martens E. Antibiotics in late clinical development. Biochem Pharmacol. 2017;133:152-63. doi: 10.1016/j.bcp.2016.09.025.
  69. Novak R. Are pleuromutilin antibiotics finally fit for human use? Ann NY Acad Sci. 2011;1241:71-81. doi: 10.1111/j.1749-6632.2011.06219.x.
  70. Zeitlinger M., Schwameis R., Burian A., et al. Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. J Antimicrob Chemother. 2016;71:1022-26. doi: 10.1093/ jac/dkv442.
  71. Sader H.S., Paukner S., Ivezic-Schoenfeld Z., et al. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). J Antimicrob Chemother. 2012;67:1170-75. doi: 10.1093/jac/dks001.
  72. Paukner S., Geione S.P., Arends S.J.R., et al. Antibacterial activity of Lefamulin against pathogens most commonly causing community-acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016). Antimicrob Agents Chemother. 2019;63:e02161-18. doi: 10.1128/AAC.02161-18.
  73. Prince W.T., Ivezic-Schoenfeid Z., Leii C., et al. Phase II clinical study of BC-3781, a Accepted Manuscript pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2013;57:2087-94. doi: 10.1128/AAC.02106-12.
  74. File T.M., Goldberg L., Das A., et al. Efficacy and safety of IV-to-Orai Lefamuiin, a pieuromutiiin antibiotic, for treatment of community-acquired bacterial pneumonia: The Phase 3 LEAP 1 Trial. Clin Infect Dis. 2019;69:1856-67. doi: 10.1093/cid/ ciz090.
  75. Gasink L. Study to compare lefamulin to moxifloxacin for the treatment of adults with pneumonia (LEAP2). 2016. Available at: https: //clinicaltrials.gov/ct2/show/NCT02813694
  76. Eyal Z., Matzov D., Krupkin M., et al. A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism. Sci Rep. 2016;6:39004.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2021

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах